Treatment of the antiphospholipid antibody syndrome: progress in the last five years?

Research output: Contribution to journalReview article

Abstract

The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.

Original languageEnglish (US)
Pages (from-to)256-261
Number of pages6
JournalCurrent rheumatology reports
Volume2
Issue number3
DOIs
StatePublished - Jun 2000

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Treatment of the antiphospholipid antibody syndrome: progress in the last five years?'. Together they form a unique fingerprint.

  • Cite this